⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 6, 2026Annals of Internal Medicine

In HIV-1, bictegravir–lenacapavir was noninferior to continued complex regimens for maintaining viral suppression at 48 wk

Peter S. Millard

View at Publisher

Ask AI

Bookmark

Share

Key Points

To compare the effectiveness of bictegravir-lenacapavir to complex regimens in maintaining viral suppression in HIV-1.
Study design
Participants assigned to bictegravir-lenacapavir or complex regimens
Follow-up duration of 48 weeks
Bictegravir-lenacapavir was noninferior to complex regimens for maintaining viral suppression at 48 weeks.
No significant differences were reported in viral load adherence between groups.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Shows bictegravir-lenacapavir maintains viral suppression in HIV-1, suggesting a simpler treatment option.

Abstract

CLINICAL IMPACT RATINGS: GIM/FP/GP: [Formula: see text] Infectious Disease: [Formula: see text].

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Peter S. Millard (2026) studied this question.

synapsesocial.com/papers/6a4f39e32b81a944af574719 https://doi.org/10.7326/annals-26-02075-jc

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline2025 · 6 citations
2Bictegravir/Lenacapavir: A 2-Drug Regimen for the Treatment of HIV-1 InfectionLate-Phase Clinical Trial · 2026
3Evaluating the combination of bictegravir and lenacapavir as a single tablet option for HIVHuman Clinical Trial · 2026
4Long-Acting Lenacapavir and Cabotegravir and Viral Suppression Among People With HIVCase Report · 2026
5Bictegravir’s effect on persistent low-level viremia and immunological response. BELAIR study: A pilot prospective observational study2025

Bictegravir’s effect on persistent low-level viremia and immunological response. BELAIR study: A pilot prospective observational study2025
Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial2024
Baseline and week 48 resistance analysis in participants receiving bictegravir + lenacapavir in the phase 2 ARTISTRY-1 study2026
MeaslesAnnals of Internal Medicine · 2026
Decompression With or Without Fusion Across Subgroups With Degenerative Lumbar SpondylolisthesisAnnals of Internal Medicine · 2026

More from Annals of Internal Medicine

More from University of New England